For more than four years, Polish patients with SMA have benefited from treatment with nusinersen. How does the therapeutic program monitoring system evaluate the efficacy, safety and effects of this therapy?
Treatment with nusinersen was introduced in Poland under reimbursement in 2019. We are currently treating 820 patients, with a full cross-section of ages and varying degrees of symptom severity at the time of therapy initiation. Through the SMPT system, we continuously track the functional status of our patients on relevant scales. The results are unequivocally positive. Perhaps even above the expectations of those who wondere...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
